FDA panel: ADHD medication risks need clarification: underlying CVD is particularly worrisome.(Mental Health)(attention deficit hyperactivity disorder ... An article from: Family Practice News

This digital document is an article from Family Practice News, published by Thomson Gale on April 15, 2006. The length of the article is 1145 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: FDA panel: ADHD medication risks need clarification: underlying CVD is particularly worrisome.(Mental Health)(attention deficit hyperactivity disorder drugs and cardiovascular and psychiatric adverse events)
Author: Elizabeth Mechcatie
Publication:Family Practice News (Magazine/Journal)
Date: April 15, 2006
Publisher: Thomson Gale
Volume: 36 Issue: 8 Page: 1(2)

Distributed by Thomson Gale